Supplementary Figure S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Key Points

Toripalimab is investigated as a second-line therapy for patients with advanced hepatocellular carcinoma.
Cytokine levels were measured before and after treatment to assess biological changes.
The study utilizes a multicenter, open-label design to gather diverse patient data.
Finding alterations in cytokines may help define responses to treatment and forecast outcomes.

Phase I study reports changes in cytokines in patients with advanced hepatocellular carcinoma, suggesting therapeutic potential.

Supplementary Figure S2. Changes in peripheral blood cytokines before and after treatment.

No takes yet. Share an insight, caveat, or question.

Zhang et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share